Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.
Radiopharmaceutical May Benefit Patients with Metastatic Prostate Cancer Sooner
August 7, 2026
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.
Tumor Organoid Tech Advances Toward a Sci-Fi Future
July 20, 2026
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. The advances represent progress in precision medicine and point to the more routine use of tumor organoids as models for evaluating and optimizing cancer treatments.
Cancer evolution study reveals biology of glioma progression
July 14, 2026
A type of brain cancer, called glioma, tends to progress toward greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.
The findings showcase the power of modern laboratory technology for illuminating cancer development, and could inform future treatments and prognostic measures for gliomas.
Discovery Could Lead to Drug Therapy for Hypopigmentation Conditions
July 14, 2026
An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators. The discovery could lead to the development of an ampyrone-derived treatment for hypopigmentation disorders.
Cancer Evolution Study by EIPM Researcher Reveals Biology of Glioma Progression
July 10, 2026
A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.
2026 Second Quarter EIPM Director's Memo
July 7, 2026
Dear Friends & Members of the Englander Institute,
Welcome to the second quarterly external newsletter of 2026!
July 2026 EIPM Director's Memo
July 2, 2026
Dear Friends & Members of the Englander Institute,
I hope you enjoy this abbreviated edition of the EIPM Director's Memo. There was a lot of content in the previous edition that covered May and the first two weeks of June, but there is still plenty to read and enjoy here.
Thank you again for your continued hard work and dedication to our mission, and best wishes for a fun & relaxing holiday weekend!
Sincerely,
Olivier Elemento, Ph.D.
Rare Stem T Cells May Hold the Key to Fighting Chronic Diseases
July 2, 2026
T cells are an elite fighting force of the immune system, seeking out and destroying diseased cells. But in a prolonged campaign against a chronic condition — like a viral infection, or cancer — the body needs a steady supply of these killer troops. Where and how these killer troops are generated has been a mystery.